Why Did Our Warrants and Conversion Features Get Classified as Liabilities?

The email from the audit senior arrives late in fieldwork: "We believe the warrants issued with the convertible notes require liability classification and quarterly remeasurement." Nothing about the economics changed. Someone finally read the settlement provisions against ASC 815-40-25, the less famous leg of the derivative scope exception, and the one that produced most of the 2021 restatement wave.

What are the two legs of the equity scope exception?

A warrant, or an embedded conversion feature, escapes derivative treatment only under ASC 815-10-15-74(a), which requires both:

1. Indexed to your own stock, the two-step test of ASC 815-40-15-7 (exercise contingencies, then fixed-for-fixed settlement); and
2. Classified in stockholders' equity, the settlement-condition analysis of ASC 815-40-25.

Companies obsess over leg one and skim leg two. But leg two is where boilerplate fails, and its organizing principle is unforgiving: equity classification requires that share settlement be within your control in every scenario the contract contemplates. Any provision that could entitle the holder to net cash on an event outside your control points to liability classification.

Which settlement conditions actually get failed?

From the conditions enumerated at ASC 815-40-25-10 and the related guidance, four failure modes account for nearly everything I see at small caps:

Insufficient authorized shares. If your authorized-but-unissued share count can't cover the maximum shares deliverable under all outstanding commitments, options, RSUs, other warrants, the conversion feature itself, share settlement isn't within your control, and equity classification fails. This is dynamic: a company fine at issuance can fail the condition mid-year after issuing more instruments, triggering reclassification then. The quarterly share-sufficiency workpaper is a control, not a formality.

No explicit share cap on variable features. Where any feature can flex the share count, the contract needs an explicit cap on maximum shares issuable. No cap, no demonstrable sufficiency, no equity classification.

Holder cash-out rights on events not solely in your control. The canonical example is the SPAC-style tender-offer provision the SEC staff flagged in its April 12, 2021 statement: if a tender or exchange offer could result in all warrant holders receiving cash while not all common shareholders do, equity classification fails. Fundamental-change make-wholes, put rights on delisting, and cash true-ups on registration failures deserve the same scrutiny, though note ASU 2020-06 softened the registration point: penalty payments for failing to deliver registered shares no longer automatically preclude equity classification, and the ASU also removed the legacy collateral and counterparty-rights conditions.

Holder-dependent settlement terms. Terms that change with the instrument's holder, the private-placement-warrant feature that broke indexation for hundreds of SPACs, technically fail leg one, but travel in the same agreements. If terms differ for the sponsor versus transferees, start there.

Feed the warrant agreement and the note's conversion section through the Convertible Debt & Embedded-Derivative Classifier at app.unfoldingvalues.com; it walks both legs clause by clause and isolates which provision drives the failure, the input you need for the next section.

Can we amend the contract to restore equity classification?

Usually yes, and this is underused. Classification follows the contract, so the contract can be fixed:

• Delete or condition the cash-settlement triggers so any cash outcome requires an event in which holders of the underlying common stock also receive cash (the fix the post-2021 SPAC market standardized on).
• Add an explicit share cap and, if needed, a shareholder-approved authorized-share increase to restore sufficiency.
• Conform holder-specific terms so settlement doesn't vary with the instrument's holder.

Two caveats. First, an amendment is a modification, analyze it before assuming it's costless; reclassification from liability to equity happens at the amendment date at fair value, not retroactively. Second, an amendment fixes the future, not the past: if the instrument was misclassified in issued financial statements, you still owe the error analysis.

Is a misclassification automatically a restatement?

No, it's a materiality question, and 2021 is instructive on both sides. Where the error was material, companies filed Item 4.02 non-reliance 8-Ks and amended filings; hundreds of SPACs did exactly that after the staff statement. Where quantitatively smaller, companies corrected through revision ("little r") in the next filing. Run SAB 99 honestly: the error misstates the liability/equity split, inserts missing fair-value volatility into earnings, and often changes loss-per-share, and where the warrant mark can exceed operating results, quantitative materiality arrives fast. Also evaluate ICFR: nearly every 2021 warrant restatement carried a companion material-weakness disclosure over accounting for complex financial instruments, and your auditor will expect the same coupling.

How do we prevent the next one?

Classification risk enters through drafting, not the accounting close. Route every term sheet, notes, warrants, ELOCs, anything with your stock on the other side, through a pre-signing classification screen at app.unfoldingvalues.com, and give treasury and legal a one-page list of banned clauses: uncapped variable share settlement, holder-dependent terms, and cash-out rights on events you don't control. Every one is negotiable before signing and expensive after.

FAQ

What single provision most often forces warrant liability classification?

Cash-settlement rights on events outside the issuer's control, the tender-offer cash-out in legacy SPAC warrant agreements, flagged in the SEC staff's April 12, 2021 statement. Authorized-share insufficiency is the runner-up, and the one that can flip classification mid-life.

Did ASU 2020-06 make equity classification easier?

Modestly. It removed or clarified three legacy ASC 815-40-25-10 conditions, unregistered-share settlement, collateral, and counterparty rights ranking. The core principle that share settlement must be within the issuer's control is unchanged.

If we amend the warrant to fix the offending clause, does the liability go away retroactively?

No. Reclassification to equity occurs prospectively at the amendment date, with the liability remeasured to fair value through earnings immediately before reclassification. Prior-period misclassification, if any, is a separate error-correction analysis.

Do we need a share-sufficiency analysis every quarter?

Yes, if any share-settleable contract relies on equity classification. Compare authorized-and-unissued shares against maximum deliverable shares across all commitments; new issuances can fail the test mid-year and force reclassification at that date.